{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
First approved in 2007
Source:
21 CFR 352
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
NCT04588480: Phase 4 Interventional Completed SARS-CoV-2 Infection
(2020)
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2025)
Source URL:
First approved in 2025
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M032
(2025)
Source URL:
First approved in 2025
Source:
M017
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2025)
Source URL:
First approved in 2025
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M006
(2025)
Source URL:
First approved in 2025
Source:
M006
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M022
(2025)
Source URL:
First approved in 2025
Source:
M022
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M032
(2025)
Source URL:
First approved in 2025
Source:
M032
Source URL:
Class:
POLYMER
